Phase I : Cediranib in Combination with Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
Study identifier:D8480C00057
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of cediranib (RECENTIN™, AZD2171) in Combination with Lomustine Chemotherapy for patients with primary recurrent malignant brain tumours for whom Lomustine would be a standard therapy
Medical condition
Recurrent Glioblastoma
Phase
Phase 1
Healthy volunteers
No
Study drug
Cediranib, Lomustine
Sex
All
Actual Enrollment
20
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2007
Primary Completion Date: 01 Dec 2008
Study Completion Date: 01 Dec 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Lomustine + Cediranib (AZD2171) | Drug: Cediranib oral tablet Other Name: RECENTIN™ Other Name: AZD2171 Drug: Lomustine oral capsule Other Name: CCNU Other Name: CeeNU® |
Contacts
Investigators
Principal Investigator
Jane Robertson
AstraZeneca
